BioNexus Gene Lab (NASDAQ:BGLC) and Laboratory Co. of America (NYSE:LH) Critical Survey

BioNexus Gene Lab (NASDAQ:BGLC) and Laboratory Co. of America (NYSE:LH) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, earnings, risk, analyst recommendations and profitability.

Profitability

This table compares BioNexus Gene Lab and Laboratory Co. of America’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioNexus Gene Lab	-27.24%	-30.74%	-25.41%
Laboratory Co. of America	3.52%	14.68%	7.03%

Analyst Ratings

This is a breakdown of recent recommendations and price targets for BioNexus Gene Lab and Laboratory Co. of America, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNexus Gene Lab	0	0	0	0	N/A
Laboratory Co. of America	0	3	11	0	2.79

Laboratory Co. of America has a consensus price target of $241.29, suggesting a potential upside of 17.03%. Given Laboratory Co. of America’s higher probable upside, analysts plainly believe Laboratory Co. of America is more favorable than BioNexus Gene Lab.

Institutional & Insider Ownership

18.9% of BioNexus Gene Lab shares are owned by institutional investors. Comparatively, 95.9% of Laboratory Co. of America shares are owned by institutional investors. 6.8% of BioNexus Gene Lab shares are owned by insiders. Comparatively, 0.9% of Laboratory Co. of America shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Earnings & Valuation

This table compares BioNexus Gene Lab and Laboratory Co. of America’s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNexus Gene Lab	$9.77 million	0.91	-$2.63 million	N/A	N/A
Laboratory Co. of America	$12.16 billion	1.43	$418.00 million	$4.97	41.48

Laboratory Co. of America has higher revenue and earnings than BioNexus Gene Lab.

Summary

Laboratory Co. of America beats BioNexus Gene Lab on 9 of the 10 factors compared between the two stocks.

About BioNexus Gene Lab

BioNexus Gene Lab Corp., through its subsidiary, sells chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company offers chemical raw material products, which include Polyester Resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; Polyester Resin 9509, a general-purpose material used in production of marine boats and water slides; and Polyester Resin 2802 used as a component in the pultrusion process by certain manufacturers. Its products are used to produce handrails, bench tops, automotive and aero parts, and paneling for hospital, laboratory, industrial clean rooms, and covers for various instruments used in manufacturing. The company also involves in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers to detect potential risk of diseases. It markets its products through its website, warehouse, marketing personnel, and suppliers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.

About Laboratory Co. of America

Laboratory Corporation of America Holdings operates as a life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Biopharma Laboratory Services (BLS). The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C and vitamin D, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations (MCOs), including health fairs, on-site and at-home testing, vaccinations, and health screenings. In addition, the company offers online and mobile applications that enable patients to check test results; online applications for providers, MCOs, and accountable care organizations; and drug development, medical device, and companion diagnostic development solutions from early-stage research to clinical development, as well as support for crop protection and chemical testing. It serves pharmaceutical, biotechnology, medical device, and diagnostics companies; and MCOs, employer plans, other health insurance providers, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, crop protection and chemical companies, academic institutions, independent clinical laboratories, and retailers. The company was incorporated in 1994 and is headquartered in Burlington, North Carolina.